InsidersTradesSigma
Track the Orchard Therapeutics plc stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Health Care sector, Orchard Therapeutics plc has recorded 10 reports. Market capitalisation: €359.6m. The latest transaction was reported on 24 January 2024 (Disposition). Among the most active insiders: THOMAS FRANK E. The full history is accessible without an account.
10
Insider Decl.
n/a
Thresholds
€16,762
2 ops.
Buy Volume
n/a
6 ops.
Sell Volume
54Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 16,052 of 28,752 companies
48.8
score / 100
Value52
Quality46
FCF yld12%
Earn yld-36%
EV/EBITDA9.2x
ROE15%
Gross mgn·
Net mgn·
Debt/EBITDA6.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 January 2024
Declarations10 total
92,081 sharesOrdinary SharesSEC:0000950170-24-007078:0
366,158 sharesOrdinary SharesSEC:0000950170-24-007058:0
12,294 sharesOrdinary SharesSEC:0000950170-24-007074:0
44,391 sharesOrdinary SharesSEC:0000950170-24-007087:0
37,179 sharesOrdinary SharesSEC:0000950170-24-007057:0
9,294 sharesOrdinary SharesSEC:0000950170-24-007064:0
20,000 shares@ US$0.459136.2% of flowOrdinary SharesSEC:0001209191-23-018327:0
20,000 shares@ US$0.459135.7% of flowOrdinary SharesSEC:0001209191-23-008578:0
15,000 shares@ US$0.7390.087% mcap100.0% of flowOrdinary SharesSEC:0001209191-22-022988:0
Canonical exit: 30 Jun 2022 (T+90)
10,000 shares@ US$0.74740.059% mcap100.0% of flowOrdinary SharesSEC:0001209191-22-022336:0
Canonical exit: 30 Jun 2022 (T+90)
10 of 10 declarations
About Orchard Therapeutics plc
Orchard Therapeutics plc is a biopharmaceutical company focused on developing gene therapies for rare diseases. It is listed on NASDAQ under the ticker symbol ORTX.